Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab vs docetaxel in advanced non-small cell lung cancer after prior platinum therapy
CTR20171112Phase 3Completed
- Sponsor
- BeOne Medicines
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by BeOne Medicines. Started Oct 2017; status: completed.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20171112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171112.